Navigation Links
ChemoCentryx to Present at The 9th World Congress on Inflammation in Tokyo, Japan
Date:7/8/2009

MOUNTAIN VIEW, Calif., July 8 /PRNewswire/ -- ChemoCentryx, Inc. today announced that Thomas J. Schall, Ph.D., ChemoCentryx's President and Chief Executive Officer, will give a keynote lecture at The 9th World Congress on Inflammation in Tokyo, Japan. Dr. Schall's lecture titled, "Treating Inflammation by Inhibition of Chemokine Receptors: Practical Requirements and Efficacy of CCR9 Antagonism in Inflammatory Bowel Disease" will be given on Thursday, July 9, 2009 at 9:00 am local time.

"It is a privilege to have been invited to speak at this prestigious gathering of thought leaders involved in the search for innovative treatments in inflammatory disease," said Thomas J. Schall, Ph.D., ChemoCentryx's President and Chief Executive Officer. "With recent regulatory approvals and clinical trial successes of chemokine-based therapeutics, this underscores the enthusiasm and promise of developing drugs that selectively inhibit specific chemokine and chemoattractant receptors in the treatment of inflammatory diseases."

About ChemoCentryx

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a network of secreted chemokine molecules, or ligands, and cell surface receptors that regulates inflammation. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has internally generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN, a specific CCR9 antagonist, is in a Phase II/III multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease. CCX025, also a CCR9 antagonist, is in a Phase I clinical trial. Additional clinical programs include the development of CCX140, which targets the CCR2 receptor, currently in a Phase I clinical trial and intended for subsequent development to treat diseases such as Type 2 diabetes, multiple sclerosis and vascular restenosis, and CCX354, a CCR1 antagonist in a Phase I clinical trial, being developed for inflammatory diseases such as rheumatoid arthritis. ChemoCentryx also has several programs in preclinical development. ChemoCentryx is privately held. For more information, please refer to www.chemocentryx.com.


'/>"/>
SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ChemoCentryx Appoints Edward E. Penhoet, Ph.D., to Board of Directors
2. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
3. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
4. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
5. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
6. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
7. AtriCure to Present at Roth Capital Partners 2007 New York Conference
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. MDS to Present at Thomas Weisel Partners Healthcare Conference
10. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
11. AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... ... and financial planning services to families and business owners in the greater Kansas ... supporting children with developmental disabilities. , The Lakemary Center is a comprehensive educational ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... the first time support an aid project with the donation of cochlear implants. ... the gift of hearing and thus a fair chance of leading an independent ...
(Date:1/17/2017)... ... 17, 2017 , ... Anesthesia Progress – Everyone wants less pain ... drug option for each patient. Dentists have several general anesthesia alternatives and finding the ... from the Tokyo Dental College in Tokyo, Japan wanted to find out which anesthetic ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... supplement, Healthful-Flex. , The company, owned and operated by Ed Stroup, was ... a reasonable price with the highest level of customer service. Healthful Balance products ...
(Date:1/17/2017)... CA (PRWEB) , ... January 17, 2017 , ... ... County, as well as Palm Desert, is opening a new office in San ... deep transcranial magnetic stimulation (dTMS) in Southern California, successfully treating individuals struggling with ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... India , January 18, 2017 According to a ... and by Application: Global Opportunity Analysis and Industry Forecast, 2014 - 2022," the ... to reach $1,127 million by 2022, growing at a CAGR of 8.26% from ... in terms of revenue. Continue Reading ... ...
(Date:1/18/2017)... , Jan 18, 2017 Research and ... and Vomiting Drugs Market 2017-2021" report to their offering. ... The global CINV ... period 2017-2021. Global Thoracic Surgery Market 2017-2021, has ... industry experts. The report covers the market landscape and its growth ...
(Date:1/18/2017)... GREENWOOD VILLAGE, Colo. , Jan. 18, 2017 /PRNewswire/ ... an independent chain of pharmacies based in ... Safe Rx™ Locking Prescription Vials (LPVs) in selected Good Day ... abuse now have a cost-effective alternative for secure storage," ... Safe Rx.  "For less than the price of a ...
Breaking Medicine Technology: